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The considerable literature dealing with
many aspects of progressive systemic sclerosis
(acroscierosis) reveals no etiologic factor as the
cause of this disease. Rodnan (1) recently re-
viewed the clinical, serological and immunohisto-
chemical evidence suggesting that it is "an ab-
normal perhaps heritably determined, immune
response." Rukavina et at. (2) gave a compre-
hensive discussion on the chemical reasons for
the possibility that scleroderma, as well as other
chronic diseases, may represent an aberration
in trace or abnormal metal actions; either a
trace metal deficiency, abnormal metal excess,
metalloensyme competition by an extraneous
metal or the dependence of many metallo-
enzyme systems upon chelation.
A derangement in calcium and/or magne-
sium metabolism would appear to be a likely
possibility as the cause of scleroderma since it
has been shown that the ubiquitous sulfated
mucopolysaccharides (found essentially in car-
tilage, tendon, heart valves, skin and the walls
of large blood vessels) serve as cation exchange
resins in a complex physiological system (3). It
was demonstrated that 1 meq of cation (cal-
cium, sodium, barium) was bound to 1 g of dry
cartilage (sulfate content 1 mecljg) and that
there was an excellent correlation between cat-
ion binding capacity and sulfate content (4).
The concepts that the extracellular fluid and
ground substance together form one physico-
chemical system (5) and the possibility that
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connective tissue which does not calcify may
accumulate calcium (6) are suggested in view
of the fact that the connective tissues of the
body contain calcium in both ionic and bound
forms in excess of that present in the blood (7).
Salts of ethylenedianiinetetraacetic acid
(EDTA) have long been used in clinical medi-
cine, as for example in the dissolution of
urinary calculi (8, 9), to dissolve metastatic
calcium deposits in the kidney (10), in the sepa-
ration, concentration and transfusion of plate-
lets (11), blood preservation (12), lead poison-
ing (13, 14), hemachromatosis (15, 16, 17, 18),
acute ferrous sulphate poisoning (19, 20, 21),
porphyria (22), plutonium poisoning (23),
corneal opacities (24), lime burns for the eye
(25), hypertension (26, 27), as a means of
lowering blood cholesterol (27, 28, 29), in
angina pectoris (10, 30) and in calcinosis
universalis (31, 32, 33). EDTA combines with
metal ions to form cyclic complexes which are
water-soluble and virtually undissociated (34).
When the sodium salt (Na,EDTA) is rapidly
administered the serum calcium is lowered and
an excess of urinary calcium is excreted. Thus
Spencer et at. (35) found that in 3 normal
individuals the actual urinary calcium excre-
tion corresponded to 73—84 per cent of the
theoretical calcium binding power of the in-
jected EDTA dose. (1 g NaEDTA complexes
108 mg calcium at a pH above 6.5).
In 1955 Klein and Harris (36) described a
severe ease of calciuic scleroderma that re-
sponded to intravenous Na2EDTA with x-ray
evidence of diminution of articular and cu-
taneous metastatic calcific deposits, and in-
creased mobility of affected joints. A post-
treatment skin biopsy specimen was reported
as indicating some clinical improvement, al-
though the illustrations are not convincing
(Table I). Stimulated by this, others treated
non-calcific cases with varying results (2, 37,
38). After a three week course (total 45 g of
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intravenous Na,EDTA) three patients im-
proved, but only one post-treatment skin biopsy
specimen showed some return to normal (2).
Nine of 23 cases improved after a three week
course of the same salt, but three sets of pre-
and post-treatment skin biopsy specimens
showed no significant change (37) (Table I).
The three patients described by Johnson in
1960 (38) were presumably those reported by
the same group in 1957 (2).
Winder and Curtis (39) treated 19 patients
with acroscler3sis with 45-135 g Na,EDTA
over 6 weeks although one had 180 gms in 8
weeks. Seven were thought to be improved,
four possibly improved and eight were un-
changed. No skin biopsy studies were done.
Birk and Rupe (40) treated thirteen cases with
the same salt with encouraging results, but
again no post-treatment skin biopsies were
performed. Most authors agreed that results
were better in the acrosclerotic type of selero-
derma (38, 39, 40, 41) but emphasized that
the ultimate usefulness of the drug had still
to be evaluated (37, 39). This group of opti-
mistic reports were brought into perspective
by a follow-up study by Neidner et al. (42)
of 60 patients two to four years after their
course of chelation therapy. These patients in-
cluded those described by Muller at at. (37)
where it had been noted that the drug was
not curative, that the response of a given indi-
vidual was unpredictable, and why improve-
ment only occurred in some eases and not in
others remained unexplained. Neidner at at.
(42) suggested that the immediate subjective
and objective (temporary) improvement could
have been related to bed-rest plus physical
therapy. The analysis revealed that repeated
courses of Na2EDTA did not increase the
chances of improvement, and that there was no
significant difference in the clinical course of
treated and untreated cases.
The present paper forms part of a larger
review of 27 patients with progressive systemic
sclerosis (PSS) seen in the same clinic over
the past four years. The clinical, pathological
and EKG aspects were presented and a scheme
outlining the pathological sequence of events
was postulated (43). In view of the fact that
previous reports dealt only with short courses
of EDTA usually totalling 45—60 g and lasting
only a few weeks with little or no histologic
change in the skin, we thought it worth while
to examine specimens of skin, both histologi-
cally and chemically, from four patients after
prolonged courses of intravenous Na2EDTA
totalling 132—212 g and given over a period of
fifteen months. In addition, two patients were
given oral tetrahydroxyquinone (THQ) for the
same period of time. Kelly and Pinkus (44)
TABLE I
Effect of Na5EDTA on skin biopsies reported in literature
Author Ref.no. Type of case
°' of
cases
Total
EDTA(s) Length oftreatment Post-treatment skinbiopsy resuits
Klein and Harris (1955)* 36 Calcific 1 60 8 weeks Improved
Rukavina et al. (1957) 2 Acroselerosis,
non-calcific
3 45 8 weeks 2 unchanged
1 minor improve-
ment
Muller et al. (1959) 37 Aeroselerosis,
non-ealcific
3 45 3 weeks No significant
change
Johnson (1960)t 38 Acrosclerosis,
non-calcific
3 45 3 weeks 1 minor improve-
ment
Present Authors — Acrosclerosis,
non-calcific
4 132—212 15 months 3 improved (Fig-
ures 1—3)
* Theonly report with photomicrographs.
t Presumably the same cases as Rukavina at at. (1957).
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reported clinical and histological regression of
keloids with this compound. The effect was
thought to be possibly via an enzyme system
or by a chelating mechanism. Eight untreated
cases of scieroderma served as histologic
controls, five as chemical controls and normal
and involved skin from the same patient were
compared. In addition, normal skin from eleven
individuals without scieroderma were analyzed
for calcium and magnesium.
MATERIALS AND METHODS
General details are furnished in Tables II—IV.
1. The four patients treated with Na5EDTA had
severe, non-calcifie acroselerosis, and each had
Raynaud's phenomenon, mask-like facies, wide-
spread skin involvement, esophageal hypomotility
and pulmonary changes with alveolar-capillary
block. In addition H. W. had a thickened perio-
dontal membrane, sclerodactyly, resorption of un-
gual tufts, gangrene of two digits necessitating
amputation, joint involvement and progressive
esophageal changes in spite of treatment with
EDTA. The EKG showed marked LAD, PAC's,
occasional PVC's and RV outflow tract hyper-
trophy.
2. The two patients treated with oral hydroxy-
quinone (THQ) also had non-calcific acroscierosis
with Rayiiaud's phenomenon and moderate skin
involvement. L. S. had esophageal hypomotility,
resorption of ungual tufts and typical changes in
the lung parenchyma. Both had pulmonary func-
tion tests at the lower limits of normal.
3. The eight untreated histologic controls were
classic cases of PSS, several very severe; six had
esophageal involvement, and three expired.
4. Three of the five untreated cases of scle-
roderma that served as chemical controls were in-
cluded in the group of histologic controls. The re-
maining two were also classic cases of PSS.
Involved and uninvolved skin from the same pa-
tients were analyzed (Table III).
5. Normal forearm skin from eleven individuals
of the same age range but without scleroderma
were chemically analyzed for comparison (Table
IV).
Therapy: Administration and Dosage
1 (a). Di.todium EDTA (Endrate: Abbott
Laboratories) was administered intravenously in
intermittent 5 day courses over 15 months on an
Histologic analyses of skin biopsies from cases of progressive systemic sclerosis before and after treatment
Cases Biopsy site Total medication Skin histology
J. B., NM 58, No. 388056 (on
digoxin and reserpine)
H. W., NF 32, No. 160588
J. G., NM 44, No. 82964
E. C., NF 43, No. 133043 (on
digoxin)
Left suprascapular region
Flexor surface, forearm
Dorsal aspect, middle pha-
lanx, left 3rd digit
Flexor surface, forearm
PT
120 EDTA
190 EDTA
PT
132 EDTA
PT
150 EDTA
212 EDTA
PT
100 EDTA
180 EDTA
Typical
Improved
(Fig. 1)
Typical
Improved
(Fig. 2)
Typical
Improved
(Fig. 3)
Typical
No change
L. S., NF 41, No. 57048
H. S., NP 55, No. 91884
Right calf
Flexor surface, forearm
PT
21.6 THQ
40.5 THQ
PT
40.5 THQ
Typical
No change
Typical
No change
* Race, sex, age and hospital number. The skin was involved at all biopsy sites.
f Na2EDTA: 0.5 gm/30 lbs body weight in intermittent five day courses over 15 months. Tetrahy-
droxyquinone (THQ): one 30mg tablet three times daily continuously. PT = pre-treatment.
TABLE II
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TABLE III
Chemical analyses of skin biopsy specimens from involved and uninvolved skin
from cases of progressive systemic sclerosis
Case
Biopsy Site pg Ca/mg skin pg Mg/mg skin
Involved Uninvolved Involved Uninvolved Involved Uninv01ved
After EDTA treatment
J. B., NM 58, No. 388056
H. W., NF 32, No. 160588
J. G., NM 44, No. 82964
E. C., NF 43, No. 133043
Left suprascapu-
lar region
Flexor surface,
forearm
Dorsal aspect,
middle pha-
lanx, left 3rd
digit
Flexor surface,
forearm
Right thigh
Left thigh
(slightly in-
volved)
Right thigh
Right thigh
.14
.15
.12
.27
.35
.15
.26
.14
.10
.15
.15
.17
.31
.14
.13
.12
After THQ treatment
L. S., NF 41, No. 57048
H. S., NF 55, No. 91884
Right leg
Flexor surface,
forearm
(slightly in-
volved)
Flexor surface,
forearm
None taken
.19
.35
.26
—
.20
.17
.21
—
Untreated cases of scieroderma
M. C., NF 36, No. 343157
A. M., NF 44, No. 90093
E. M., NM 55, No. 2947
R. C., NM 56, No. 471253
P. M., NP 65, No. 129347
Right upper arm
Right wrist
Middle phalanx,
right 3rd digit
Flexor surface,
left forearm
Flexor surface,
right forearm
Left thigh
Left thigh
Left thigh
None taken
Right thigh
.24
.29
.20
.30
.23
.16
.28
.21
—
.26
.16
.13
.13
.15
.24
.13
.21
.17
—
.17
* Race, sex, age and hospital number. Biopsies of involved skin in the first six cases were taken ad-
jacent to their previous biopsies.
outpatient basis. One half a gram per 30 lbs body
weight was dissolved in 500 cc of 5 per cent glu-
cose in water and infused over one hour. The total
dose ranged from 132—212 g depending on body
size.
,Side effects: These were minimal and did not
necessitate discontinuation of therapy. A sensation
of localized burning at the infusion site sometimes
occurred, and two patients had gastric irritation,
controlled by antacids. The patient H. W. is de-
scribed below.
(b). The patient H. W. (for clinical details see
above) had intermittent courses of magnesium-
EDTA (Abbott Laboratories) over 15 months
from January, 1962 to March, 1963, with a total
dose of 152.5 g without any side effects. However,
therapy was discontinued because there was severe
infection and gangrene of the fingers; and the
possible effect of this salt on infection was not
known. Amputation of two digits was performed
in July, 1963. Na2EDTA was started in February,
1964 and continued until May, 1965 with a total
dose of 132 g during which time serial esopha-
grams demonstrated further dilatation of the
esophagus. As noted above, the EKG was abnor-
mal, probably due to pulmonary and/or cardiac
involvement. On one occasion, near the beginning
of disodium salt therapy, the patient had mild
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hypocalcemia with cramps in the calves, a positive
Chvostek's sign and cardiac arrhythmia. These
signs and symptoms were quickly relieved by in-
travenous calcium. Throughout this second course
the patient experienced attacks of dizziness and
palpitations, but an EKG taken during an attack
only showed sinus tachycardia.
2. Thirty mg of tetrahydroxyquinone (THQ)
was taken three times a day continously for 15
months. There were no side effects.
Skin biopsy specimens were taken from the
same involved sites before, during and at the end
of treatment. The histologic specimens were em-
bedded in paraffin, cut and stained with hema-
toxylin and eosin, orcein-Giemsa, Mallory and
Von Kossa's method for calcium. All the sections
were stained at one time in order to eliminate
variation in stain.
The samples for chemical onelysis were stored
fresh frozen and were likewise analyzed at one
time. They were lyophylized, digested with a
perchloric-nitric mixture, the salts then taken up
in water and spectrographed for calcium and
magnesium using lithium as an internal standard.
RESULTS (TABLES is—v)
General. The four patients treated with
Na2EDTA cooperated well and there was sub-
jective and objective softening of the skin.
However, there was no evidence of improve-
ment in the viscera as judged by esophagrams
and x-rays of the lung parenchyma. In fact H.
W. developed gangrene of two digits while on
MgEDTA, necessitating amputation, and pro-
gressive esophageal involvement while on
Na2EDTA.
One patient (H. S.) on THQ did not exhibit
any significant change. The other (L. S.) who
had more cutaneous involvement, noticed some
softening of the skin, but this was not as
marked as in those patients receiving
Na2EDTA.
Histology (Table II)
Sections of all the untreated cases of sclero-
derma showed severe changes consisting of
broadening of the collagen bundles, leading to
more or less complete obliteration of inter-
fascicular spaces. The papillary layer was simi-
larly involved and the vaseularity of the
papillae was reduced even where the pattern of
epidermal ridges was preserved, as it was in the
majority of eases.
The pre-treatment specimens of the experi-
mental group showed similar changes, and no
significant differences were observed after
treatment with THQ and in one of the eases
E. J., NF 33,
No. 331951
P. D., NF 34,
No. 334791
B. C., NF 38,
No. 124412
V. P., NF 45,
No. 325386
H. B., NM 65,
No. 461774
F. F., WM 71,
No. 367694
All normal skin from the volar aspect of the
forearm or the thigh.
treated with EDTA (E. C.). In the other three
EDTA eases, the following changes were
found: J. B.: pre-treatment sections of skin
from the suprascapular region showed the epi-
dermis was only 3—4 cell layers thick, heavily
pigmented and covered by a dense horny layer.
Epidermal ridges were largely absent. The con-
nective tissue of the dermis was very dense,
and the normal difference between the papil-
lary and reticular layers was almost lost.
Fibrocytes and capillary blood vessels were
sparse, the vessels appeared rigid and there
was a considerable number of pigmented
macrophages in the upper dermis (Fig. JA).
TABLE IV
Chemical analyses of eleven normal skin
biopsy specimens
Case
B. B., NF 29,
No. 265007
K. C., NF 32,
Biopsy site
Right forearm
Left thigh
Left forearm
Left forearm
Left forearm
Left forearm
Right forearm
Left forearm
Left forearm
Left forearm
Left forearm
pgCa 5gMg
mgskio mgskin
.20 .12
.38 .31
.25 .12
.32 .23
.25 .19
.37 .15
.25 .21
.43 .23
.31 .15
.32 21
.36 .16
A. C., NF 54,
No. 357464
A. M., NM 58,
No. 177068
A. 1%., WM 59,
No. 367670
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FIG. 1. Sections of suprascapular skin of J.B., H and E, X 170. A. before treatment, B.
after 190 gm EDTA. The large triangular or stellate cells in the upper dermis in A. are
pigmented macrophages.
FIG. 2. Sections of skin from the flexor surface of the forearm of 11W., 11 aad E, X 170.
A. before treatment, B. after 132 gm EDTA.
Sections taken after 190 g of EDTA showed
no great change in the lower part of the
epidermis, but the horny layer was more
loosely woven and was similar to normal skin.
The dermal collagen formed thinner and more
wavy bundles separated by interfascicular
spaces. The blood vessels and fixed tissue cells
appeared more nearly normal, and the number
of pigmented macrophages was much reduced
(Fig. 1B).
11. W.: The epidermis of the flexor sur-
face of the forearm was of average thickness
before and after treatment, although the horny
layer was somewhat more dense in the pre-
treatment specimen. The dermal collagen was
far less sclerotic before treatment than in J. B.,
but the normal structural difference between
papillary and reticular layers was obliterated.
Fibrocytes were scarce and the small blood
vessels were rigidly open (Fig. 2A). Sections
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taken after 132 g EIDTA showed improve-
ment in the condition of fibers, cells and blood
vessels (Fig. 2B).
J. G.: Biopsy specimens were taken from
the dorsal aspect of the middle phalanx of the
left third finger. Before treatment the skin was
so sclerotic that difficulty was experienced in
cutting the sections (Fig. 3A). The epidermis
was not much thinner than normal, but the
dermal collagen was so dense that all struc-
tural details were lost. Fibroblasts and capil-
laries were scarce. After 150 g of EIDTA the
collagen bundles of the retieular layer were
well defined though still thick (Fig. 3B), the
papillary collagen remained dense, but the
capillaries were fairly normal. The epidermis
had the average configuration for this part of
the body and was covered by extremely thick,
dense keratin. Two months after completion of
the course of 212 g of the drug there was addi-
tional improvement (Fig. 3C) especially in the
epidermis and papillary connective tissue. The
malphighian and granular layers of the epi-
dermis were thicker, the horny layer was
thinner and less dense. The dense eollagenous
zone at the lower border of the epidermis was
thinner, and the population of cells in the
dermis had increased. In spite of matched stath-
ing, the dermal collagen appeared lighter than
in Fig. 3B, presumably because the bundles
were thinner.
The Von Kossa stains on all the sections
were negative, whether they were untreated,
pre-treatment or post-treatment specimens. It
should be noted that the effect of MgEDTA on
H. W. was not evaluated, since the remedy was
given before the main research program was
begun. She received 152 g over 15 months, the
course ending one year prior to the pre-treat-
ment biopsy for the course of Na2EDTA which
is recorded.
Chemistry
Calcium and magnesium determinations were
made on skin biopsy specimens from 11 nor-
mal donors as well as from the uninvolved
and involved sites from 11 patients suffering
from scleroderma. The latter group comprised
4 patients treated with EDTA, two treated
with THQ and the remainder untreated. Nor-
mal calcium values (Table IV) were .29 tg
per mg dry weight with a standard deviation
FIG 3. Sections of dorsal skin of the finger of J.G., H and E, X 153. A. before treat-
ment, B. after 150 gm EDTA, C. two months after completion of the full course of 212 gm.
The poor condition of the section shown in A. is due to the extreme sclerosis which made
cutting difficult.
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of .07 while the seleroderma average (Table
III) ran .23 .07 pg/mg dry skin. The differ-
ence is not significant statistically. However,
closer inspection shows that the specimens from
the involved sites of the three patients who
responded histologically to EDTA treatment all
show calcium levels at the lower end of the
overall range (Table V). This was not true
for E. C., the patient who also failed to show
histological improvement. The magnesium val-
ues for normals were .19 .05; for the group
with scleroderma .17
.05 cg/mg dry tissue.
Literature averages for the two metals quoted
by Rothman (45) are 27—46 mg per 100 g dry
skin for calcium and 18—30 mg per 100 g dry
skin for magnesium. The same author points
out that the calcium content of skin increases
with increasing age. Analysis of the 11 control
specimens show a slight trend in this direction.
The same correlation is somewhat more marked
in the twenty seleroderma samples. It was not
possible to establish any correlation of mag-
nesium values in skin with age.
DISCUSSION
Histologic findings. Three of the four pa-
tients treated with EDTA showed a return
toward normal in their skin biopsy specimens,
while there was no significant difference in the
two treated with THQ. These results are far
better than those recorded in the literature
(Table I). This is probably related to the
much greater dose and far longer time of ad-
ministration (15 months as against 3—8 weeks).
All the EDTA eases had definite softening of
the skin clinically, as did one of the patients on
THQ who had a similar though milder response.
The decreased vaseularity and loss of inter-
faseieular spaces in the eorium of the pretreat-
ment specimens is felt clinically as stiff, hard
skin; while the increased vaseularity, return
of fixed tissue cells and the loosening of the
collagen bundles in the dermis as well as the
horny layer of the epidermis is reflected as
clinical softening. The reappearance of the
(normal) interfascieular spaces denotes a new
influx of ground substance which allows a more
normal passage of nutrient and waste ma-
terials to and from the cells. As these biopsy
specimens were non-calcifie (Von Kossa nega-
tive and a normal calcium content) the ob-
served softening could not have been due to
loss of calcium, and suggests that EDTA acts
on the connective tissue itself, probably via
the parathyroids as discussed below.
Biopsy site. The biopsy specimens were
TABLE V
Summary of chemical analyses
case no. of cases Age Range(yr)
No. of
biopsies
pg Ca/mg skin
Average and range
pg Mg/mg skin
Average and range
Normal controls 11 29—71 11 .29 (.20—43) .19 (.12—31)
Seleroderma
Untreated
Involved skin
Urnnvolved skin
After EDTA
Involved skin
Uninvolved skin
After THQ
Involved skin
Uninvolved skin
5
4
2
36—65
32—58
41—55
5
4*
4
4t
2
1*
.25 (.20—30)
.23 (.16—28)
.17 (.12—27)
.25 (.14—35)
.27 (.19—35)
.26
.16 (.13—24)
.17 (.13—21)
.14 (.10—17)
.18 (.12—.31)
.19 (.17—20)
* One patient in each group had no biopsy of uninvolved skin.
t One patient had no uninvolved skin and biopsy from a lesser involved area gave similar values to
the severely involved area.
Rothman45 qnotes average figures from the literature for human skin: calcium 27—46 mg/100 g dry
tissue and magnesium 18—30 mg/100 g dry tissne.
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taken from the same skin areas at intervals of
about 8 months. Therefore, the second and
third specimens were near a previous area of
healing, but this transient increase in local
metabolic activity could not have been the
cause of the changes observed as only three
of the six cases that underwent serial study
demonstrated any alteration.
Relation to calcium and magnesium
The normal skin calcium and magnesium
levels obtained throughout this study confirm
Rothman's refutation of the older belief that
calcium is retained by patients with sclero-
derma (45). He found normal values in the
uninvolved skin of one patient with sciero-
derma and a normal calcium balance and nor-
mal excretion of excess calcium administered
by mouth or by injection. "Thus the reason
why scieroderma is so often associated with
calcinosis remains obscure (and) requires fur-
ther study." He also points out that "nothing
is known about the distribution, linkages, and
physiological role of calcium in the corium ex-
cept that it represents a vital constituent of
the cementing substance of the endothelial
cells.... There is some indirect evidence that
calcium may be bound to connective tissue
fibers in a non-ionized form." The only striking
response to EDTA by a scieroderma patient
reported in the literature was the calcific case
of Klein and Harris (36) (Table I). It is
noteworthy, therefore, that three of the EDTA
treated non-calcific cases discussed in this re-
port responded both clinically and histologi-
cally. It may be relevant that E. C. was taking
digoxin for congestive heart failure, but J. B.
(who responded histologically) was also on this
drug, in addition to reserpine, for hypertensive
heart failure. The possible influence of these
medications, as well as differences in individual
response on the outcome of EDTA therapy,
requires further study.
The fact that the involved, but not the un-
involved, sites of the EDTA treated patients
who responded histologically to EDTA showed
relatively low calcium values suggests that the
action of EDTA is on the abnormal non-
calcific collagen bundles.
Boyle and co-workers (46) discuss the possi-
ble mechanisms by which EDTA affects the
connective tissue in a wide range of circula-
tory and scierosing diseases. They point out
that Na,EDTA initially lowers the ionic cal-
cium in the blood, so that which is not carried
to bone is replenished from tissue sources and
calcium turnover is increased, aided by the
known, concurrent alteration in cell membrane
permeability. This, they suggest, stimulates a
parathyroid response which is largely responsi-
ble for many effects for example, the differ-
ence in time manifestation of atherosclerosis in
the sexes owing to the cyclical stimulation of
parathyroid activity in the female. They also
mention the effect of NaEDTA on trace metals
with possible secondary enhancement or inhibi-
tion of enzyme systems, though such an argu-
ment is far less tenable in view of the fact that
administration of CaEDTA does not show the
effects obtained with the sodium or magnesium
salts.
Trace metals and enzyme systems
The progressive sclerosis throughout the body
in scieroderma points to a possible defect in
proteolysis. Three well-characterized proteolytic
enzymes have been demonstrated in the skin
(47): two dermo-proteases and a peptidase
(48, 49, 50, 51). These are believed to play
significant roles in trauma, vesiculation and
inflammation of the skin. Cathepsins (47) are
ubiquitous components of animal tissues espe-
cially kidney, spleen, liver and lung, and are
involved in autolysis of dead tissues. They
are also present in lysosomes and may play an
important role in many diseases.
Although a mammalian collagenase has long
been suspected (52) especially in relation to
the involuting post-partum uterus, only re-
cently has real evidence of its existence been
forthcoming. buck and Patel (53) found that
the alkaline extract of porcine pancreas was
collagenolytic, and that it was not inhibited
by EDTA, soybean trypsin inhibitor or mer-
curobenzoate, and was not enhanced by the
addition of CaCl2 thus ruling out contamina-
tion with bacterial collagenase, the presence of
a "collagen mucoproteinase", a denatured col-
lagen or a non-specific cathepsin as possible
causes of the collagen breakdown.
Yet another possible mechanism of action
stems from a series of papers by the same
group (54, 55, 56, 57, 58). They found a loss of
insoluble collagen from the uninjured skin of
animals away from the area of trauma. This
was termed the "distant dermal collagen re-
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sponse" and was found to occur following local
croton oil injury; administration of cortisol, or
stress in the form of sham adrenalectomy or
daily intraperitoneal injections of large amounts
of isotonic saline. It could be mediated by
local tissue enzyme release as suggested by their
most recent paper (59) where extracts of in-
tact and necrotic rat skin were shown to exhibit
collagenolytic activity that was riot inhibited
by EDTA, soybean trypsin inhibitor or a
mercuric salt. Collagenolytic activity has also
been demonstrated in bone cells (60), this
activity being entirely confined to the intra-
cellular large granule fraction that sediments
between 700 and 15,000 g (61).
it is conceivable that the stress of intrave-
nous infusions of Na,EDTA could have played
a part in the loss of dermal collagen demon-
strated histologically, either by (1) stimulation
of parathormone, (2) direct activation of local
autologous proteolytic enzymes (dermopro-
teases; cathepsins), (3) stimulation of endoge-
nous pancreatic collagenase (presuming human
and porcine pancreas possess the same en-
zymes) or (4) stimulation of endogenous corti-
sone which is known to depress fiber forma-
tion. The first is the most likely, since the
parathyroids are known to respond to lowering
of the serum ionic calcium and parathor-
mone in turn is known to cause collagen break-
down (62). Although the mechanism of this
turnover has not yet been established it is
quite possible that a collagenase intermediary
is involved. In fact, the addition of parathy-
roid extract enhances the release of hydroxy-
proline from rat bone in tissue culture by a
collagenolytic process (63).
The second and third suggestions remain as
intriguing possibilities with far-reaching impli-
cations. For example, if the pancreas secretes
collagenase, this would be continuous through-
out life but would fluctuate according to re-
quirements, e.g. increasing post-partum and
possibly slowly decreasing throughout life, thus
allowing sclerosis to occur in sites such as blood
vessels. It is interesting that the administration
of porcine pancreatic collagenase to a patient
with severe PSS produced a definite though
temporary response, as evidenced by a decrease
in skin content of hydroxyproline and an in-
creased urinary excretion of hydroxyproline
(64).
The last suggestion seems quite unlikely as
the stress would appear too slight to produce
sufficient cortisone; nor has intravenous ad-
ministration of either the sodium or magnesium
salts of EDTA resulted in an elevated urinary
output of 17 hydroxy corticoids (65). Finally,
in animal experimentation, "control" groups re-
ceived as many injections of physiological saline
as the "treated" groups received of EDTA. The
marked differences obtained between two such
groups (66) must then be due to something
other than the "stress of the injection".
Our results suggest a long chain of effects
ending in enzymatic tissue breakdown. To our
knowledge this is the first study of its kind,
and is worthy of further investigation of a
larger number of patients, preferably not on
cardiac drugs. In addition, this approach may
be developed to elucidate the ill-understood,
altered enzyme systems in disease (for exam-
ple, the collagenolytic activity of normal and
pathologic human skin could be studied before
and after various treatments or modes of
stress).
SU1%MARY
The skin from four patients with progres-
sive systemic sclerosis were examined before
and after a prolonged course of intravenous
Na2EDTA totalling 132—212 gm over fifteen
months. Two patients were similarly studied
following 40 g of tetrahydroxyquinone (THQ)
by mouth, and all were compared with cases of
untreated scieroderma as well as with normal
controls. Three of four patients treated with
EDTA showed histological improvement
whereas the remainder were unchanged.
The calcium and magnesium content of both
involved and uninvolved skin from treated and
untreated cases of scieroderma were within the
range of normal controls similarly studied, and
were also within the ranges quoted in the
literature (45). However, the involved skin
samples from the three histologically-respon-
sive patients exhibited calcium levels that were
below the range of the normal controls.
The literature on the rationale and thera-
peutic use of EDTA is reviewed, and the possi-
ble mechanisms underlying the results are dis-
cussed with special reference to endogenous
proteolytic enzymes. It is suggested that this
approach could be modified to study altered
enzyme systems in human disease.
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